Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories disputes and clarifications
52 filed, newest first. Page 1 of 2.
Oct 2026
Apr 2026
Mar 2026
Jan 2026
Sep 2025
Aug 2025
May 2025
Apr 2025
Feb 2025
Dec 2024
Nov 2024
Sep 2024
Jun 2024
26 Jun · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 07-Jun-2024, regarding " Dr. Reddy's Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015'.". On basis of above the Company is required to provide the parameters As per PARA-A Sub Para-20, of the SEBI circular dated July 13, 2023. The response of the Company is awaited.
May 2019
Apr 2019
25 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Feb 2019
Oct 2018
19 Oct · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 15-Oct-2018, regarding regarding a press release dated October 15, 2018, titled "Dr. Reddy's Laboratories announces the sale of its API manufacturing business unit in Jeedimetla, Hyderabad ".". On basis of above the Company is required to clarify following: 1. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.2. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";3. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.4. Consideration received from such sale/disposal;5. The expected date of completion of sale/disposal;6. Date on which the agreement for sale has been entered into;7. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;The response of the Company is awaited.
Jul 2018
25 Jul · Legal
Exchange has sought clarification from the Company with respect to news item captioned- AstraZeneca sues DRL on patent In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.16 Jul · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 14-Jul-2018, regarding " Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 14, 2018, titled "Press Release".". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty etc; 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation; The response of the Company is awaited.
Jun 2017
14 Jun · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Dr Reddy's recalls 3.25L cartons Cipla-made acne drug from US". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Mar 2017
6 Mar · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated March 03, 2017, regarding a press release dated March 03, 2017, titled "Dr. Reddy's Laboratories announces acquisition of 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC). On basis of above the Company is required to clarify following: 1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Brief details of any governmental or regulatory approvals required for the acquisition;4. Indicative time period for completion of the acquisition;5. Nature of consideration - whether cash consideration or share swap and details of the same;6. Percentage of shareholding / control acquired and / or number of shares acquired;7. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
Feb 2017
16 Feb · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 16-Feb-2017, regarding a press release dated February 16, 2017, titled "Dr. Reddy's announces US district court's opinion relating to patent infringement."On basis of above the Company is required to clarify following: 1. Expected financial implications, if any, due to compensation, penalty etc;2. Quantum of claims, if anyThe response of the Company is awaited.
Jan 2017
27 Jan · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Korean Company files suit against DRL In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Aug 2015
Jun 2015
Mar 2015
11 Mar · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned "DRL may buy Belgian co's India ops for $135m". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. . If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under clause 36 of the Listing Agreement. The response from the Company is awaited.
Jan 2015
9 Jan · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Maharashtra suspends Dr Reddy's licenses". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
26 Dec · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Indian pharma now under Canada lens . The Company has clarified that : In keeping with current regulations of Health Canada, the Company has voluntarily placed under quarantine all APIs and the formulations based on APIs produced at our API facility in Srikakulam district of Andhra Pradesh intended for use in Canada. Our products continue to meet intended quality standards, and we believe that, our APIs and Finished drug products manufactured using these APIs pose no risk to the health and safety of the Canadian people. The Company is working with the agency for a satisfactory resolution of the matter. At this stage, it has no implication on any activity at the plant and hence, these are not expected to be material to the Company s operations or consolidated results.26 Dec · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Indian pharma now under Canada lens". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.11 Dec · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "Dr. Reddy s through its local entity Betapharm is proceeding in line with the instructions of the regulator. Overall impact on the financials of this action is expected to be non-material".11 Dec · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
27 Nov · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item dated November 27, 2014, captioned "Srikakulam plant gets Form 483 for lapses: DRL". In this regard Company has clarified as under: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. The Company has received some inspectional observations from the US FDA after their visit to our API manufacturing facility in Srikakulam district of Andhra Pradesh. The Company is committed to respond to the agency within stipulated timelines with our remedial plans and start implementing the necessary measures immediately. At this stage, it has no implication on any activity at the plant. Hence, these are not expected to be material to the Company's operations or consolidated results. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under clause 36 of the Listing Agreement. For reasons stated in response to question (a) above, we did not see a stock exchange notification necessary.27 Nov · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned "Srikakulam plant gets Form 483 for lapses: DRL". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
9 Oct · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "On October 2, 2014, Dr. Reddy s Laboratories Ltd. received notice from US Congress Committees on price escalation of its generic products of Divalproex Sodium ER and Pravastatin Sodium. The Company has strict internal policies of complying with all applicable statutes and regulatory requirements of markets in which it operates, globally. The Company is of the opinion that it has complied with all applicable product pricing norms. Also, Company's Divalproex Sodium ER marketing approval was received well after all market price increases were put in place by competitors. Company does not now market Pravastatin Sodium. Company is responding to the US Congress letter well within time. As it stands today, Company does not see the notice material to its operations or consolidated results".